Loading chat...
IN HB1150
Bill
Status
1/9/2017
Primary Sponsor
Joe Taylor
Click for details
AI Summary
-
Office of the Secretary of Family and Social Services must identify prescription drugs covered under Medicaid with annual wholesale acquisition cost or per-course treatment cost of at least $10,000
-
Drug manufacturers must file annual reports with the drug utilization review board by May 1 each year, covering at least five years before investigational drug application through new drug application approval
-
Required report contents include production costs (R&D, clinical trials, materials, manufacturing), marketing and advertising costs, pricing history, profit attribution, patient assistance amounts, and failed research project costs
-
Independent third-party auditors must verify all report information before manufacturers may file, and the board may request additional information or establish filing forms and requirements
-
Drug utilization review board must keep proprietary and confidential information protected and submit annual summaries to the general assembly for posting on its Internet website
-
Effective date: July 1, 2017
Legislative Description
Prescription drug cost reporting. Requires the office of the secretary of family and social services to identify any prescription drug under the Medicaid program for which the annual wholesale cost or the per course cost of treatment of the drug is at least $10,000, and directs the office to notify the manufacturer that the manufacturer is required to prepare a report on the drug to the drug utilization review board (board). Specifies requirements of the report. Authorizes the board to request additional information, establish forms, and specify other requirements that a manufacturer must meet in the filing of the report.
Last Action
First reading: referred to Committee on Public Health
1/9/2017